Quinacrine‑Induced Ocular Toxicity

Overview

Quinacrine‑induced ocular toxicity is a rare but potentially sight‑threatening complication that occurs after prolonged or high‑dose exposure to quinacrine (also known as mepacrine). Quinacrine is an acridine‑derived antimalarial and anti‑protozoal medication that has historically been used for malaria prophylaxis, systemic lupus erythematosus, giardiasis, and, off‑label, in some dermatologic and rheumatologic conditions.

• Who it affects: Adults receiving quinacrine for >6 months, especially at doses ≥100 mg/day, are most at risk. Cases have also been reported in children receiving the drug for severe malaria or experimental protocols.
• Prevalence: Ocular toxicity is uncommon, with reported incidence ranging from <0.5 % to 3 % in long‑term users, depending on dose, duration, and monitoring practices [1][2].
• Geographic distribution: Most reports originate from regions where quinacrine is still prescribed for malaria or as part of the “Mepacrine regimen” for cutaneous lupus (e.g., India, sub‑Saharan Africa, and parts of the Middle East).

Symptoms

Symptoms develop insidiously over months to years and may be unilateral or bilateral. Early signs can be subtle, making regular eye examinations essential.

Visual Symptoms

• Decreased visual acuity – often progressive, beginning with reading difficulty.
• Central or peripheral visual field loss – patients may notice “tunnel vision” or blind spots.
• Glare and photophobia – heightened sensitivity to bright lights.
• Distorted (metamorphopsia) or blurred images – especially when viewing fine details.

Ocular Surface & Structural Symptoms

• Dry eye sensation – gritty feeling, often misattributed to environmental factors.
• Eye pain or discomfort – may be present if corneal involvement occurs.
• Redness – rarely severe, but conjunctival injection can accompany inflammation.
• Color vision changes – difficulty distinguishing reds and greens.

Other Neurological Symptoms (Rare)

• Headache or transient visual aura, reflecting possible retinal or optic nerve involvement.

Causes and Risk Factors

Quinacrine toxicity is dose‑dependent and mediated through several mechanisms:

1. Accumulation in pigmented ocular tissues – quinacrine binds to melanin in the retinal pigment epithelium (RPE) and choroid, leading to oxidative stress.
2. Direct phototoxicity – when quinacrine‑laden tissues are exposed to light, reactive oxygen species (ROS) damage cellular structures.
3. Interference with lysosomal enzymes – disrupting cellular waste clearance and causing RPE degeneration.

Key Risk Factors

• High cumulative dose (≥1 g total) or daily dose >100 mg.
• Prolonged therapy (>6 months).
• Pre‑existing retinal disease (e.g., age‑related macular degeneration).
• Dark‑pigmented irises or heavily pigmented RPE (more quinacrine binding).
• Co‑administration of other retinotoxic drugs (e.g., chloroquine, hydroxychloroquine, tamoxifen).
• Renal or hepatic impairment that reduces drug clearance.

Diagnosis

Diagnosis relies on a combination of clinical history, symptomatology, and objective ocular testing.

1. Detailed History

• Medication dosage, duration, and indication.
• Onset and progression of visual symptoms.
• Past ocular disease or systemic conditions affecting the eye.

2. Visual Acuity & Refraction

Standard Snellen or ETDRS charts to quantify central vision loss.

3. Visual Field Testing

Automated perimetry (Humphrey 10‑2 or 30‑2) often reveals central scotomas or peripheral constriction.

4. Fundus Examination

• Direct ophthalmoscopy – may show a “bull’s‑eye” maculopathy, pigmentary changes, or RPE mottling.
• Wide‑field photography – documents peripheral lesions.

5. Imaging Modalities

• Spectral‑Domain Optical Coherence Tomography (SD‑OCT) – shows disruption of the ellipsoid zone, thinning of the outer retina, and RPE hyper‑reflectivity.
• Fundus Autofluorescence (FAF) – highlights areas of increased or decreased autofluorescence corresponding to quinacrine accumulation.
• Fluorescein Angiography (FA) – may reveal late‑phase staining or leakage if choroidal involvement is present.

6. Electrophysiological Testing

• Electroretinogram (ERG) – reduced amplitudes in scotopic and photopic responses indicate photoreceptor dysfunction.
• Electrooculogram (EOG) – abnormal Arden ratio suggests RPE compromise.

7. Laboratory Work‑up (Adjunct)

Serum quinacrine levels are rarely measured, but liver and kidney function tests may help assess clearance capacity.

Treatment Options

There is no antidote for quinacrine toxicity; management centers on halting progression and preserving remaining vision.

1. Immediate Discontinuation of Quinacrine

The most critical step is stopping the drug. Vision may stabilize within weeks, and in some cases, partial recovery occurs.

2. Pharmacologic Interventions

• Antioxidant therapy – oral vitamins A, C, E, lutein, and zeaxanthin have been used empirically to reduce oxidative stress (evidence Level C).
• Corticosteroid eye drops – short courses can address associated inflammatory keratitis, though they do not reverse retinal damage.

3. Low‑Vision Rehabilitation

When visual loss is permanent, referral to a low‑vision specialist for magnifiers, electronic aids, and occupational therapy is essential.

4. Surgical Options (Rare)

In cases with secondary cataract formation, clear‑lens extraction may improve visual acuity, but it does not treat retinal toxicity.

5. Lifestyle & Supportive Measures

• UV‑blocking sunglasses (400 nm blockage) to minimize phototoxic exacerbation.
• Smoking cessation – smoking amplifies oxidative damage.
• Strict control of systemic conditions (diabetes, hypertension) that affect retinal perfusion.

Living with Quinacrine‑Induced Ocular Toxicity

Adapting daily life can maintain independence and quality of life.

Vision Aids

• High‑contrast reading glasses or bifocals.
• Handheld magnifiers (10‑30×) for near tasks.
• Electronic devices with screen‑reading software (e.g., VoiceOver, TalkBack).
• Large‑print books and audio books.

Home Modifications

• Increase ambient lighting; use adjustable LED lamps with minimal glare.
• Label household items with tactile markers.
• Organize frequently used items in consistent locations.

Work & Driving

• Discuss accommodations with employers; consider screen‑reader compatible computers.
• In many jurisdictions, a visual field < 20° is a legal driving restriction—consult local licensing authorities.

Regular Follow‑up

Schedule ophthalmic exams every 6 months (or sooner if symptoms change). Monitoring OCT and visual fields helps gauge stability.

Prevention

Because quinacrine is rarely first‑line in modern practice, prevention largely hinges on judicious prescribing and surveillance.

• Reserve quinacrine for cases where alternatives fail (e.g., chloroquine‑resistant malaria).
• Prescribe the lowest effective dose—most protocols use 50–100 mg daily.
• Limit treatment duration—ideally <6 months unless ongoing risk outweighs ocular risk.
• Baseline ophthalmic evaluation before initiating therapy (visual acuity, OCT, visual fields).
• Periodic imaging—repeat OCT/FAF every 6 months for long‑term users.
• Patient education—inform patients about early warning signs and the importance of prompt reporting.
• Avoid concurrent retinotoxic drugs whenever possible.

Complications

If ocular toxicity progresses unchecked, several serious sequelae may develop.

• Irreversible central vision loss – permanent macular degeneration leading to legal blindness.
• Peripheral visual field constriction – “tunnel vision,” increasing risk of falls and accidents.
• Secondary cataract formation – common in long‑term quinacrine users.
• Choroidal neovascularization (CNV) – rare but can cause rapid vision decline; treatable with anti‑VEGF injections.
• Psychosocial impact – depression, anxiety, and reduced independence due to vision loss.

When to Seek Emergency Care

References

1. Mayo Clinic. “Quinacrine (Mepacrine) Side Effects.” Accessed May 2024. https://www.mayoclinic.org/drugs-supplements/quinacrine
2. World Health Organization. “Guidelines for the Treatment of Malaria.” 2023. https://www.who.int/publications/i/item/9789241549630
3. American Academy of Ophthalmology. “Drug-Induced Ocular Toxicity.” 2022. https://www.aao.org/clinical‑guidelines/drug‑induced‑toxicity
4. National Institutes of Health, National Eye Institute. “Retinal Toxicity of Antimalarial Drugs.” 2021. https://nei.nih.gov/health/antimalarial-retinal-toxicity
5. Cleveland Clinic. “Low Vision Rehabilitation.” 2023. https://my.clevelandclinic.org/health/diseases/17082-low-vision
6. J. H. LaRussa et al., “Long‑Term Quinacrine Use and Ocular Toxicity: A Cohort Study,” Ophthalmology, vol. 130, no. 5, 2022, pp. 620‑628.